The document summarizes an innovative respiratory device called AMS-H-03 that provides oxygen and hydrogen gas to COVID-19 patients. It can effectively treat symptoms and provide life support. Clinical studies have shown almost all patients' symptoms and oxygen levels improved after one week of treatment. The device has received approval for use in China's COVID-19 treatment protocols.

1. AMS-H-03
H :66.6%
O :33.3%2
2

2. AMS-H-03 is national innovative Class Ⅲ respiratory device, which can supply patients with one
liter of oxygen and two liters of hydrogen per minute (H2/O2:66.69%/33.3%). It covers COVID-19
patients in different stages of infection (mild, moderate, severe or critical). It can not only effectively
ameliorate eight symptoms of fever, cough, sputum, polypea, chest tightness, chest pain, dyspnea,
and peripheral oxygen saturation (SpO2), but also provide life support. Moreover, the device has up
to 177 patents, and its safety is subject to the most stringent controls. Presently, oxyhydrogen
therapy has been included in the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7)
and the Diagnosis and Treatment Protocol for Severe and Critical Cases of COVID-19 (Trial Version
3) in China. WHO has translated the seventh version of the diagnosis and treatment protocol into
English for the reference of member countries. This innovative Chinese technology is now attracting
increasing attention.
Product Description
Product Parameters

3. In terms of clinical manifestations, COVID-19 is characterized by fever, which may be accompa-
nied by mild dry coughing, fatigue, difficulty breathing, and diarrhea. Other symptoms such as a runny
nose and sputum are rare. Half of the patients developed dyspnea one week after illness onset .In
severe cases, patients progressed rapidly to acute respiratory distress syndrome, septic shock,
metabolic acidosis, and coagulopathy. In terms of imaging findings, multiple small patchy shadows and
stromal changes were observed in the early stage, which were obvious in the periphery of the lungs,
and then developed into multiple ground-glass opacities and infiltrates in both lungs. In severe cases,
lung consolidation may occur. Pleural effusions are rare. In addition to the imaging findings, patients
may also have normal or lower peripheral WBC counts and lower lymphocytes counts. In some
patients, liver enzymes, muscle enzymes and myoglobin were elevated. In most patients, the level of
C-reactive protein and the erythrocyte sedimentation rate were elevated, and the level of procalcitonin
was normal. In severe cases, D-dimer increased and lymphocytes decreased progressively.
In the case of acute inflammation, most of the alveoli are blocked and filled with inflammatory
exudate, and it is particularly important to improve the gas exchange efficiency of the remaining alveoli.
The inhalation of a nebulized mixture of hydrogen and oxygen gases has the physical effect of
increasing the gas dispersion and flow rate. Meanwhile, hydrogen can reduce malignant free radicals
such as hydrocarbon radicals (OH) and nitrite anions (ONOO). Its anti-inflammatory effects can
effectively prevent airway remodeling and pulmonary fibrosis, reduce goblet cell proliferation, improve
lung function, counteract the side effects of taking hormones in large doses, eliminate the large number
of free radicals generated due to lung damage after the virus' invasion into the body.
The Mechanism of Action of Oxyhydrogen Therapy (H2/O2
66.6%/33.3%) on COVID-19
At the urgent request of Professor Zhong Nanshan, academician of the Chinese Academy of
Engineering (CAE),
Asclepius Meditec has launched a clinical project on the treatment of COVID -19 through the
inhalation of a mixture of hydrogen and oxygen gases (Scientific Research A) and conducted a
real-world clinical study protocol on the efficacy of the adjuvant therapy of the inhalation of a mixture of
hydrogen and oxygen gases for COVID-19 patients (Scientific Research B).
Clinical Studies of COVID-19 in Connection with Hydrogen
Oxygen Ventilator
AMS-H-03 AND
COVID-19

4. The results of Scientific Research B showed that after one week of treatment with the inhalation
of hydrogen and oxygen gases, almost all patients' symptoms and peripheral oxygen saturation
improved, and the severity of the disease decreased. Statistical processing showed that after days of
treatment with the inhalation of hydrogen and oxygen gases, all the above indicators were significantly
different from those before treatment.
Meanwhile, Scientific Research A is still in progress, and preliminary data also show the general
effectiveness of treatment. The results of this phase of research will be published after the statistics
processing is obtained.
Guangzhou Eighth People's Hospital THE Third People's Hospital of Shenzhen
Wuhan Hanyang Hospital Dongguan Ninth People's Hospital
Wuhan Hankou Hospital Leishenshan Hospital
Wuhan Red Cross Hospital Wuhan Third People's Hospital
The First Affiliated Hospital of Nanchang University
No.1 Hospital of Suihua City, Heilongjiang Province
Qiqihar Medical University, Heilongjiang Province
Infectious Disease Hospital of Heilongjiang Province
Harbin Hospital for Infectious Diseases, Heilongjiang Province
And hospitals in Jingzhou, Wuhan
Efficacy of Oxyhydrogen Therapy (H2/O2 66.6%/33.3%) for
COVID-19:
Academician Zhong said:
Video link
Video link
Patients who participated in the clinical trial said:
https://ascleway.cn/video/PatientVideo1.mp4
https://ascleway.cn/video/PatientVideo2.mp4
https://ascleway.cn/video/PatientVideo3.mp4
https://ascleway.cn/video/PatientVideo4.mp4
https://ascleway.cn/video/AcademicianZhongVideo1.mp4
https://ascleway.cn/video/AcademicianZhongVideo2.mp4
https://ascleway.cn/video/AcademicianZhongVideo3.mp4
Designated units participating in this clinical study:

5. Official Oxyhydrogen Therapy (H2/O2 66.6%/33.3%) Protocol
Diagnosis and Treatment Protocol for Novel
Coronavirus Pneumonia
(Trial Version 7)
(Released by National Health Commission & State Administration of
Traditional Chinese Medicine on March 3, 2020)
Since December 2019, multiple cases of novel coronavirus pneumonia (NCP) have been
identified in Wuhan, Hubei. With the spread of the epidemic, such cases have also been
found in other parts of China and other countries. As an acute respiratory infectious disease,
NCP has been included in Class B infectious diseases prescribed in the Law of the People's
Republic of China on Prevention and Treatment of Infectious Diseases, and managed as an
infectious disease of Class A. By taking a series of preventive control and medical
treatment measures, the rise of the epidemic situation in China has been contained to a
certain extent, and the epidemic situation has eased in most provinces, but the incidence
abroad is on the rise. With increased understanding of the clinical manifestations and
pathology of the disease, and the accumulation of experience in diagnosis and treatment,
in order to further strengthen the early diagnosis and early treatment of the disease, improve
the cure rate, reduce the mortality rate, avoid nosocomial infection as much as possible and
pay attention to the spread caused by the imported cases from overseas, we revised the
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6) to
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).
I. Etiological Characteristics
The novel coronaviruses belong to the β genus. They have envelopes, and the particles are
round or oval, often polymorphic, with diameter being 60 to 140 nm. Their genetic
characteristics are significantly different from SARS-CoV and MERS-CoV. Current
research shows that they share more than 85% homology with bat SARS-like coronaviruses
(bat-SL-CoVZC45). When isolated and cultured in vitro, the 2019-nCoV can be found in
human respiratory epithelial cells in about 96 hours, however it takes about 6 days for the
virus to be found if isolated and cultured in Vero E6 and Huh-7 cell lines.
Most of the knowledge about the physical and chemical properties of coronavirus comes
from the research on SARS-CoV and MERS-CoV. The virus is sensitive to ultraviolet and
heat. Exposure to 56°C for 30 minutes and lipid solvents such as ether, 75% ethanol,
Usage scenario
Released by the Medical Treatment Unit of the
Guidance Group of the Central Government
Released by WTO

6. Website Official
Benny.lin
+8613774356437
benny.lin09288@ascleway.com
After-sales service
Service hours: Monday to Friday 9:00-17: 00
(rest on holidays)
Feedback E-Mail: benny.lin09288@ascleway.com
Manufacturer information
Tel: 13774356437
Postal code: 201818
Registrant/manufacturer/after-sales service provider:
Shanghai Asclepius Meditec Co., Ltd.
Domicile: Building 3, No.758, Jiaxin Road, Jiading District,
Shanghai, China
Website: www.ascleway.org
www.asclepiusmeditec.com